Results 61 to 70 of about 31,072 (153)

A Dose‐Tailored Anti‐Plasma Cell Regimen Lowers the Mortality of Late‐Stage Cardiac Amyloidosis

MedComm, Volume 6, Issue 7, July 2025.
The present study was designed to assess the efficacy and safety of a dose‐tailored BD regimen and a dose‐tailored DBD regimen in patients with LCCA at Mayo Stage III. Both the two regimens markedly increased survival rate and time in those patients and the dose‐tailored DBD regimen was superior to the dose‐tailored BD regimen in both efficacy and ...
Yun Ti, Huaitao Yu, Ying Wang, Mei Ni, Tongtao Liu, Luqun Wang, Cheng Zhang, Peili Bu, Yun Zhang   +8 more
wiley   +1 more source

Report of the Scientific Committee of the Spanish Agency for Food Safety and Nutrition (AESAN) on the effects of climate change on the risk of transmission of foodborne pathogens

Food Risk Assess Europe, Volume 3, Issue 3, July 2025.
Abstract The Scientific Committee of the Spanish Agency for Food Safety and Nutrition (AESAN) has carried out an updated review of the scientific evidence on the influence of climate change on the transmission of foodborne pathogens. This global phenomenon represents an emerging threat to food safety and public health, since alterations in weather ...
Antonio Valero Díaz, Rosa María Capita González, Baltasar Mayo Pérez, Azucena del Carmen Mora Gutiérrez, María Dolores Rodrigo Aliaga, Gloria Sánchez Moragas, Paula Arrabal Durán   +6 more
wiley   +1 more source

Anderson-Fabry, the histrionic disease: from genetics to clinical management

Cardiogenetics, 2013
Anderson-Fabry disease (AFD) is an Xlinked lysosomal storage disorder of glycosphingolipid catabolism, due to deficiency or absence of a galactosidase A (α-gal A) enzyme. The disease may affect males and females, the latter with an average 10 years
Franco Cecchi, Benedetta Tomberli, Amelia Morrone   +2 more
doaj   +1 more source

Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England

ESC Heart Failure, Volume 12, Issue 3, Page 2034-2046, June 2025.
Abstract Aims Describe patient characteristics, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs associated with patients who were diagnosed with obstructive hypertrophic cardiomyopathy (HCM) in clinical practice in England.
Faizel Osman, Carla L. Zema, Michael Hurst, Belinda Sandler, Florence Brellier, Ovie Utuama, Oksana Kirichek, John Houghton, Teresa Lemmer, Maite Tome Esteban   +9 more
wiley   +1 more source

Free‐Breathing Ungated Radial Simultaneous Multi‐Slice Cardiac T1 Mapping

Journal of Magnetic Resonance Imaging, Volume 61, Issue 6, Page 2587-2600, June 2025.
Background Modified Look‐Locker imaging (MOLLI) T1 mapping sequences are acquired during breath‐holding and require ECG gating with consistent R‐R intervals, which is problematic for patients with atrial fibrillation (AF). Consequently, there is a need for a free‐breathing and ungated framework for cardiac T1 mapping.
Johnathan V. Le, Jason K. Mendes, Konstantinos Sideris, Erik Bieging, Spencer Carter, Josef Stehlik, Edward V. R. DiBella, Ganesh Adluru   +7 more
wiley   +1 more source

Clinical prodromes of neurodegeneration in Anderson-Fabry disease [PDF]

, 2015
To estimate the prevalence of prodromal clinical features of neurodegeneration in patients with Anderson-Fabry disease (AFD) in comparison to age-matched ...
Hughes, D, Reichmann, H, Milligan, A, Mehta, A, Löhle, M, Richfield, L, Schapira, AH   +6 more
core  

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy

, 2002
Background-Although studies have suggested that "late-onset" hypertrophic cardiomyopathy (HCM) may be caused by sarcomeric protein gene mutations, the cause of HCM in the majority of patients is unknown.
Tei, C, B. Sachdev, Takenaka, T, W. J. Mckenna, Sachdev, B, H. Teraguchi, Elliott, PM, Teraguchi, H, C. Tei, P. Lee, T. Takenaka, McKenna, WJ, Lee, P, Hypertrophic Cardiomyopathy   +13 more
core  

When Should Cardiologists Suspect Anderson-Fabry Disease?

, 2010
Anderson-Fabry disease is a lysosomal storage disorder caused by α-galactosidase defects and progressive intracellular accumulation of globotriaosylceramide. The disease can be specifically treated with enzyme replacement therapy.
Eliana Disabella, Maurizia Grasso, Alan G. Fraser, Alessandra Serio, Narula, Jagat, Eloisa Arbustini, B.M.E. Valentina Favalli, Serio, Alessandra, Favalli, B.M.E. Valentina, Fabiana I. Gambarin, Grasso, Maurizia, Agozzino, Manuela, Marta Diegoli, Manuela Agozzino, Gambarin, Fabiana I., Luigi Tavazzi, Diegoli, Marta, Jagat Narula, Arbustini, Eloisa, Disabella, Eliana, Tavazzi, Luigi, Fraser, Alan Gordon   +21 more
core   +1 more source

Otological aspects of Fabry disease in patients with normal hearing [PDF]

, 2019
2019-08We investigated the otological aspects of Fabry disease (FD) in patients with normal hearing. Forty-one patients (21 men, 20 women) with bilaterally normal hearing were recruited, and their otological symptoms and hearing evaluations, which ...
Sone, Michihiko, Wang, Fei, Sugimoto, Satofumi, Yamamoto, Hiroshi, Teranishi, Masaaki, Tsuboi, Kazuya, Yoshida, Tadao   +6 more
core   +1 more source

Cutaneous manifestations of Fabry disease: A systematic review

The Journal of Dermatology, Volume 52, Issue 4, Page 571-582, April 2025.
Abstract Fabry disease (FD) is a rare X‐linked lysosomal storage disorder resulting in potential debilitating accumulation of glycosphingolipids in organs such as skin, nerves, heart, kidneys, lungs, and the central nervous system. Skin is easily investigated and can guide clinicians to diagnose FD, minimizing delay of enzyme substitution therapy. This
Rami Nabil Al‐Chaer, Mathias Folkmann, Nina Løth Mårtensson, Ulla Feldt‐Rasmussen, Mette Mogensen   +4 more
wiley   +1 more source